Réalisées par des traducteurs professionnels, des entreprises, des pages web ou traductions disponibles gratuitement.
kynstofn
race
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
hvítur kynstofn
white
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
svartur kynstofn 59
black 59 %
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
kynstofn (hvítir/svartir/asískir)
race (white/black/asian) %
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
kyn, aldur eða kynstofn höfðu ekki áhrif á tíðni aukaverkana ipreziv.
the incidence of adverse reactions with ipreziv was not affected by gender, age, or race.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
Þýðisgreining á lyfjahvörfum victrelis benti til að kynstofn hefði engin augljós áhrif á útsetningu.
population pharmacokinetic analysis of victrelis indicated that race had no apparent effect on exposure.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
hins vegar er aðeins hægt að draga ályktanir fyrir hvítan kynstofn og asíubúa því of fáir einstaklingar voru í hinum hópunum.
however, conclusions can only be drawn for the caucasian and asian groups as there were too few subjects in the other categories.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
takmarkaðar upplýsingar gefa til kynna að kyn, kynstofn og þyngd hafi ekki meiri háttar áhrif á plasmaþéttni fídaxómísíns eða op-1118.
limited data suggest that gender, weight and race do not have any major influence on the plasma concentration of fidaxomicin or op-1118.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
20% lækkun á auc fyrir naloxegol þegar aðrir hópar eru bornir saman við hvítan kynstofn) og því er ekki þörf á skammtaðlögun.
the effect of race on the pharmacokinetics of naloxegol is small (approximately 20% decrease in the auc of naloxegol when other groups are compared to caucasian) and, therefore, no dose adjustment is necessary.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
samþætt greining úr öllum klínísku rannsóknunum sýndi að kynstofn, aldur, kyn, ástand nýrna- eða lifrar hefur ekki áhrif á lyfjahvörf cetuximabs.
an integrated analysis across all clinical studies showed that the pharmacokinetic characteristics of cetuximab are not influenced by race, age, gender, renal or hepatic status.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
lýðfræðilegar upplýsingar (kyn, aldur og kynstofn) sjúklinga og eiginleikar við upphaf meðferðar var sambærilegt hjá hópnum sem fékk raltegravir 400 mg tvisvar á dag, og lyfleysuhópnum.
patient demographics (gender, age and race) and baseline characteristics were comparable between the groups receiving raltegravir 400 mg twice daily and placebo.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
lýðfræðilegar upplýsingar (kyn, aldur og kynstofn) sjúklinga og eiginleikar við upphaf meðferðar var sambærilegt hjá hópnum sem fékk raltegravir 400 mg tvisvar á dag og hópnum sem fékk 600 mg efavirenz fyrir svefn.
patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving raltegravir 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :
miðgildi aldurs var 71 ár (á bilinu 42-93) og dreifing kynstofna var sem hér segir: 77% af hvítum kynstofni, 10% af asískum kynstofni, 2% af svörtum kynstofni og 11% af öðrum kynstofni eða kynstofn ekki þekktur.
the median age was 71 years (range 42-93) and the racial distribution was 77% caucasian, 10% asian, 2% black and 11% other or unknown races.
Dernière mise à jour : 2017-04-26
Fréquence d'utilisation : 1
Qualité :